RNA · Atrium Therapeutics, Inc.
$11.57
+0.03 (+0.26%)
At close · Jul 27
Market Cap
$196.54M
Shares
17.11M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$11.57
Open$11.61
Day$11.46–11.80
52W$11.40–16.77
Avg vol 30d201K
Short int3.6M · 21.0% float · 17.7d
Short vol79%
Last earningsMay 14, 2026
DataFeb 2026–Jul 2026
Filing10-Q · May 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Limited
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−8%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
3%
near low
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
23 of 163 funds reported for Jun 30 · net +226.0K sh shares · +10 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
20.99% of float · ▼ -1.8% MoM · 17.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
163 holders — 13F breadth
Squeeze score
77
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
47%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
4.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−8%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
3%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
23 of 163 funds reported for Jun 30 · net +226.0K sh shares · +10 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
20.99% of float · ▼ -1.8% MoM · 17.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
163 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $11
Now $12 · 3%
52-wk high $17
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RNA
this stock
Atrium Therapeutics, Inc.
|
$196.54M | — | — | — | 21.0% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.16B | +5.7% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.78B | -13.5% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$57.44B | +5.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RNA | -4.8% | -9.5% | — | -14.0% | — |
| SPY | -0.6% | +0.7% | +6.8% | -1.0% | +8.4% |
| vs SPY | -4.2% | -10.1% | — | -13.0% | — |
Key facts
CIK
2093101
CUSIP
04965N104
13F (30d)
21 filings
21 filers
Visit website
Investor relations